CHICAGO, Nov. 20, 2013 /PRNewswire/ -- Stocks featured in this week's Zacks Industry Rank analysis include Enanta Pharmaceuticals Inc. (Nasdaq: ENTA-Free Report) and Sucampo Pharmaceuticals (Nasdaq: SCMP-Free Report).
Zacks Industry Rank Analysis is written by John Blank, PhD, Chief Equity Strategist, Zacks.com.
Prescription for Profit
It seems every ailment has a cure and every cure, an ailment. Browsing the drug store, you can't help but feel like "there's a pill for that," as prescribed by Dr. Siri. On the other hand, side effects need to be monitored closely. One could draw a similar parallel to investing in pharmaceuticals.
The Medical/Drugs sector of the Zacks Industry Rank list gained 33 positions last week -- significant movement for a sector comprised of 97 companies. After this booster, the industry now holds a rank of #56 out of 260 ranked industries. With positive earnings revisions outpacing negative 143 to 74, the average positive Earnings per Share (EPS) surprise of +10% is remarkable given the size of the sector.
Two of the biotech and pharmaceutical companies have a particularly positive prognosis, moving last week to a Zacks Rank #1 (Strong Buy) from a "Buy" or "Hold" rating. This could signal positive future performance for these stocks in response to future positive earnings estimate revisions. While a good indicator of industry health, it's equally important to understand the fine-print details when mixing with other investments.
Take a look at the following companies and see if they could give your portfolio a needed shot in the arm.
ENTA was upgraded to a Zacks Rank #1 (Strong Buy) last week from #3 (Neutral). Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as the hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Consider its strong position in royalties on sales of ABT-450, its low-cost profile could be just the ticket for continued profitability.
Its last earnings surprise was +30%.
SCMP is a Zacks Rank #1 (Strong Buy). It moved up from a Zacks Rank #2 (Buy) last week.
Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders.
Sucampo's last earnings surprise was +400%. 2014 consensus EPS estimates are still drifting higher. This company reports quarterly earnings on March 12, 2014.
Zacks "Profit from the Pros" e-mail newsletter offers continuous coverage of the industries and the stocks poised to outperform the market. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2564.
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Len Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3:1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit From the Pros by going to http://at.zacks.com/?id=2565.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/ZacksInvestmentResearch
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Contact: Terry Ruffolo
SOURCE Zacks Investment Research, Inc.